Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease

Highlights • The serotonergic system plays a key role in LID. • The SSRI citalopram is able to fully counteract LID in 6-OHDA-lesioned rats. • Citalopram also suppressed LID in MPTP-treated macaques but affected L-DOPA efficacy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuroscience 2015-07, Vol.298, p.389-396
Hauptverfasser:	Fidalgo, C, Ko, W.K.D, Tronci, E, Li, Q, Stancampiano, R, Chuan, Q, Bezard, E, Carta, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis of Variance Animals Antiparkinson Agents - adverse effects citalopram Citalopram - therapeutic use Cognitive science Disease Models, Animal dopamine dyskinesia Dyskinesia, Drug-Induced - drug therapy Dyskinesia, Drug-Induced - etiology Dyskinesia, Drug-Induced - metabolism Female Levodopa - adverse effects Life Sciences Macaca Macaca fascicularis Male MPTP Poisoning - chemically induced MPTP Poisoning - drug therapy Neurology Neuroscience Oxidopamine - toxicity Parkinson Disease - drug therapy Parkinson Disease - etiology Parkinson’s disease Rats Rats, Sprague-Dawley serotonin Serotonin Plasma Membrane Transport Proteins - metabolism Serotonin Uptake Inhibitors - therapeutic use Time Factors Tyrosine 3-Monooxygenase - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • The serotonergic system plays a key role in LID. • The SSRI citalopram is able to fully counteract LID in 6-OHDA-lesioned rats. • Citalopram also suppressed LID in MPTP-treated macaques but affected L-DOPA efficacy.
ISSN:	0306-4522 1873-7544
DOI:	10.1016/j.neuroscience.2015.04.027